Table 3 Summary of multivariate Cox proportional hazards regression analysis of effect of BMI and each study variable on overall mortality, breast cancer mortality, and recurrence in full models
Overall mortality | Breast cancer mortality | Recurrence | |||||||
|---|---|---|---|---|---|---|---|---|---|
Variable | HRa | 95% CI | P -value | HR | 95% CI | P -value | HR | 95% CI | P -value |
Body mass index, k/m2 | |||||||||
<18.5 | 0.98 | 0.53, 1.79 | 0.945 | 0.95 | 0.48, 1.85 | 0.871 | 0.77 | 0.43, 1.37 | 0.377 |
18.5 to 24.9 | 1.00 | 1.00 | 1.00 | ||||||
25.0 to 29.9 | 0.95 | 0.80, 1.12 | 0.549 | 1.01 | 0.84, 1.22 | 0.905 | 1.03 | 0.89, 1.19 | 0.728 |
30.0 to 34.9 | 0.98 | 0.79, 1.20 | 0.814 | 1.02 | 0.81, 1.29 | 0.860 | 1.07 | 0.89, 1.29 | 0.460 |
≥35 | 1.35 | 1.06, 1.72 | 0.016 | 1.32 | 1.00, 1.74 | 0.053 | 1.25 | 0.99, 1.57 | 0.052 |
Age | |||||||||
Per 5 years | 0.92 | 0.87, 0.97 | 0.003 | 0.86 | 0.81, 0.92 | <0.001 | 0.84 | 0. 80, 0.89 | <0.001 |
Menopausal status | |||||||||
Postmenopausal | 1.00 | 1.00 | 1.00 | ||||||
Premenopausal | 0.60 | 0.48, 0.74 | <0.001 | 0.56 | 0.44, 0.71 | <0.001 | 0.64 | 0.53, 0.77 | <0.001 |
Pathologic primary tumor size | |||||||||
T1 | 1.00 | 1.00 | 1.00 | ||||||
T2 | 1.82 | 1.56, 2.32 | <0.001 | 1.87 | 1.57, 2.22 | <0.001 | 1.67 | 1.46, 1.91 | <0.001 |
T3 | 1.88 | 1.40, 2.53 | <0.001 | 2.07 | 1.51, 2.84 | <0.001 | 1.71 | 1.31, 2.23 | <0.001 |
Histological grade | |||||||||
1 | 1.00 | 1.00 | 1.00 | ||||||
2, 3, or unknown | 1.26 | 1.07, 1.48 | 0.006 | 1.32 | 1.10, 1.58 | 0.003 | 1.24 | 1.07, 1.43 | 0.004 |
Type of surgery | |||||||||
Mastectomy | 1.00 | 1.00 | 1.00 | ||||||
Conservative | 0.82 | 0.70, 0.95 | 0.008 | 0.83 | 0.70, 0.98 | 0.028 | 0.84 | 0.74, 0.96 | 0.011 |
Estrogen receptor/progesterone receptor | |||||||||
Both negative | 1.00 | 1.00 | 1.00 | ||||||
Any positive | 0.56 | 0.48, 0.64 | <0.001 | 0.51 | 0.44, 0.60 | <0.001 | 0.66 | 0.57, 0.75 | <0.001 |
Unknown | 0.85 | 0.51, 1.44 | 0.558 | 0.89 | 0.52, 1.54 | 0.689 | 1.10 | 0.69, 1.75 | 0.699 |
Human epidermal growth factor-2 status | |||||||||
Negative | 1.00 | 1.00 | 1.00 | ||||||
Positive | 1.19 | 1.00, 1.42 | 0.048 | 1.23 | 1.01, 1.49 | 0.037 | 1.23 | 1.05, 1.44 | 0.009 |
Unknown | 1.00 | 0.82, 1.23 | 0.965 | 1.11 | 0.89, 1.38 | 0.361 | 1.09 | 0.91, 1.30 | 0.335 |
Undertreatment | |||||||||
None | 1.00 | 1.00 | 1.00 | ||||||
Epirubicine <85% | 2.36 | 1.18, 4.72 | 0.015 | 3.06 | 1.47, 6.36 | 0.003 | 1.84 | 0.93, 3.63 | 0.078 |
Cyclophosph <85% | 0.86 | 0.35, 2.13 | 0.74 | 0.93 | 0.34, 2.53 | 0.880 | 1.31 | 0.58, 2.95 | 0.519 |
Fluorouracil <85% | 0.64 | 0.30, 1.34 | 0.235 | 0.45 | 0.19, 1.07 | 0.069 | 0.50 | 0.26, 0.99 | 0.046 |
Doxorubicin <85% | 1.86 | 0.89, 3.88 | 0.097 | 1.86 | 0.82, 4.22 | 0.134 | 1.29 | 0.63, 2.64 | 0.478 |
Docetaxel <85% | 0.84 | 0.46, 1.53 | 0.559 | 0.70 | 0.35, 1.40 | 0.315 | 0.75 | 0.44, 1.28 | 0.294 |
Paclitaxel <85% | 1.37 | 0.90, 2.09 | 0.147 | 1.06 | 0.62, 1.81 | 0.824 | 1.15 | 0.78, 1.70 | 0.491 |